Aurelio Maggio

List of Publications by Year
in descending order

171 papers	5,001 citations	100601 38 h-index	134545 62 g-index
171 all docs	171 docs citations	171 times ranked	4063 citing authors

#	Article	IF	Citations
1	Primary HBB gene mutation severity and longâ€term outcomes in a global cohort of Î²â€thalassaemia. British Journal of Haematology, 2022, 196, 414-423.	1.2	8
2	Very early prenatal diagnosis of Cockayneâ€™s syndrome by coelocentesis. Journal of Obstetrics and Gynaecology, 2022, , 1-8.	0.4	4
3	Lentiviral globin gene therapy with reduced-intensity conditioning in adults with Î²-thalassemia: a phase 1 trial. Nature Medicine, 2022, 28, 63-70.	15.2	18
4	Celomic Fluid: Laboratory Workflow for Prenatal Diagnosis of Monogenic Diseases. Molecular Diagnosis and Therapy, 2022, 26, 239-252.	1.6	3
5	Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. Thalassemia Reports, 2022, 12, 14-23.	0.1	3
6	Early prenatal diagnosis of Hb Lepore Bostonâ€Washington and Î²â€thalassemia on fetal celomatic DNA. International Journal of Laboratory Hematology, 2022, 44, 796-802.	0.7	2
7	Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2022, 97, .	2.0	19
8	National networking in rare diseases and reduction of cardiac burden in thalassemia major. European Heart Journal, 2022, 43, 2482-2492.	1.0	25
9	The use of hydroxyurea in the real life of MIOT network: an observational study. Expert Opinion on Drug Safety, 2022, , 1-8.	1.0	2
10	A complication risk score to evaluate clinical severity of thalassaemia syndromes. British Journal of Haematology, 2021, 192, 626-633.	1.2	7
11	Survival and causes of death in 2,033 patients with non-transfusion-dependent Î²-thalassemia. Haematologica, 2021, 106, 2489-2492.	1.7	25
12	The International Hemoglobinopathy Research Network (<scp>INHERENT</scp>): An international initiative to study the role of genetic modifiers in hemoglobinopathies. American Journal of Hematology, 2021, 96, E416-E420.	2.0	14
13	Genotypic groups as risk factors for cardiac magnetic resonance abnormalities and complications in thalassemia major: a large, multicentre study. Blood Transfusion, 2021, 19, 168-176.	0.3	3
14	Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematology,the, 2020, 7, e469-e478.	2.2	39
15	CMR for myocardial iron overload quantification: calibration curve from the MIOT Network. European Radiology, 2020, 30, 3217-3225.	2.3	12
16	Longitudinal followâ€up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: a cohort study. British Journal of Haematology, 2020, 191, 107-114.	1.2	10
17	Longâ€term sequential deferiprone and deferasirox therapy in transfusionâ€dependent thalassaemia patients: a prospective clinical trial. British Journal of Haematology, 2019, 186, e209-e211.	1.2	4
18	Double Heterozygosity for Hb Durham-N.C. (HBB: c.344T>C) [Î²114(G16)Leuâ†'Pro] and the IVS-I-110 (HBB: c.93-21G>A) Causing a Severe Î²-Thalassemia Phenotype. Hemoglobin, 2019, 43, 210-213.	0.4	0

#	Article	IF	Citations
19	Current challenges in the management of patients with sickle cell disease â€“ A report of the Italian experience. Orphanet Journal of Rare Diseases, 2019, 14, 120.	1.2	24
20	Cardiac involvement by CMR in different genotypic groups of thalassemia major patients. Blood Cells, Molecules, and Diseases, 2019, 77, 1-7.	0.6	9
21	Efficacy of Ruxolitinib as Inducer of Fetal Hemoglobin in Primary Erythroid Cultures from Sickle Cell and Beta-Thalassemia Patients. Thalassemia Reports, 2019, 9, 8101.	0.1	1
22	Fetal aneuploidy diagnosed at celocentesis for early prenatal diagnosis of congenital hemoglobinopathies. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 312-321.	1.3	8
23	Left Ventricular Diastolic Dysfunction in Î²-Thalassemia Major with Heart Failure. Hemoglobin, 2018, 42, 68-71.	0.4	15
24	Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach. European Heart Journal Cardiovascular Imaging, 2018, 19, 299-309.	0.5	74
25	Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood, 2018, 131, 263-265.	0.6	45
26	Co-inheritance of HBB:c.â^'106Gâ€‰›â€‰C, a rare single nucleotide variation at position â^'56 relative to transcription initiation site, with other known mutations in the globin clusters. Hematology, 2018, 23, 368-372.	0.7	0
27	Longitudinal changes in <scp>LIC</scp> and other parameters in patients receiving different chelation regimens: Data from <scp>LICNET</scp>. European Journal of Haematology, 2018, 100, 124-130.	1.1	5
28	Phenotypic evaluations of HBB:c.93-23T>C, a nucleotide substitution in the IVS I nt 108 of Î²-globin gene. Journal of Clinical Pathology, 2018, 71, 298-302.	1.0	0
29	Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. International Journal of Molecular Sciences, 2018, 19, 681.	1.8	8
30	Î²-Thalassemia heterozygote state detrimentally affects health expectation. European Journal of Internal Medicine, 2018, 54, 76-80.	1.0	10
31	Human coelomic fluid investigation: A MS-based analytical approach to prenatal screening. Scientific Reports, 2018, 8, 10973.	1.6	28
32	Granulocyteâ€“Colony Stimulating Factor plus Plerixafor in Patients with Î²-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ Cells with Specific Gene Expression Profile. Thalassemia Reports, 2017, 7, 6392.	0.1	2
33	Pattern of complications and burden of disease in patients affected by beta thalassemia major. Current Medical Research and Opinion, 2017, 33, 1525-1533.	0.9	40
34	The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major. British Journal of Haematology, 2017, 178, 676-688.	1.2	39
35	The heterozygote state for Î²â€thalassemia detrimentally affects health outcomes. American Journal of Hematology, 2017, 92, E23-E25.	2.0	4
36	Phenotypic Evaluation of a Novel Nucleotide Substitution (HBD: c.442T>C) on the Î´-Globin Gene. Hemoglobin, 2017, 41, 220-222.	0.4	0

#	Article	IF	Citations
37	HBB: c.316-125A>G and HBB: c.316-42delC: Phenotypic Evaluations of Two Rare Changes in the Second Intron of the HBB Gene. Hemoglobin, 2017, 41, 234-238.	0.4	2
38	The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the majorâ€intermedia dichotomy?. British Journal of Haematology, 2017, 176, 124-130.	1.2	47
39	Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6Âyears. British Journal of Clinical Pharmacology, 2017, 83, 593-602.	1.1	9
40	Study on hydroxyurea response in hemoglobinopathies patients using genetic markers and liquid erythroid cultures. Hematology Reports, 2016, 8, 6678.	0.3	8
41	Evaluation of IPF counting on Mindray BCâ€6800 hematology analyzer. International Journal of Laboratory Hematology, 2016, 38, e89-92.	0.7	2
42	Embryoâ€fetal erythroid cell selection from celomic fluid allows earlier prenatal diagnosis of hemoglobinopathies. Prenatal Diagnosis, 2016, 36, 375-381.	1.1	16
43	Realâ€life experience with liver iron concentration <scp>R</scp>2 <scp>MRI</scp> measurement in patients with hemoglobinopathies: baseline data from <scp>LICNET</scp>. European Journal of Haematology, 2016, 97, 361-370.	1.1	9
44	Identification of embryoâ€“fetal cells in celomic fluid using morphological and shortâ€tandem repeats analysis. Prenatal Diagnosis, 2016, 36, 973-978.	1.1	13
45	The Sea Urchinsns5Chromatin Insulator Shapes the Chromatin Architecture of a Lentivirus Vector Integrated in the Mammalian Genome. Nucleic Acid Therapeutics, 2016, 26, 318-326.	2.0	4
46	Coinheritance of a Rare Nucleotide Substitution on theÎ²-Globin Gene and Other Known Mutations in the Globin Clusters: Management in Genetic Counseling. Hemoglobin, 2016, 40, 231-235.	0.4	4
47	New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 278-281.	0.3	0
48	Hb San Cataldo [Î²144(HC1)Lysâ†'Thr;HBB: C.434Aâ€‰>â€‰C]: A New Hemoglobin Variant with Increased Affinity for Oxygen. Hemoglobin, 2016, 40, 223-227.	0.4	2
49	Coâ€heredity of silent <scp>CAP</scp> + 1570 T>C (<scp>HBB</scp>:c*96T>C) defect and severe Î²â€thal mutation: a cause of mild Î²â€thalassemia intermedia. International Journal of Laboratory Hematology, 2016, 38, 17-26.	0.7	8
50	The Italian multiregional thalassemia registry: Centers characteristics, services, and patientsâ€™ population. Hematology, 2016, 21, 415-424.	0.7	12
51	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. Digestive and Liver Disease, 2016, 48, 650-655.	0.4	11
52	Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5â€year longâ€term <scp>I</scp>talian multicenter randomized clinical trial. American Journal of Hematology, 2015, 90, 634-638.	2.0	35
53	Myocardial fibrosis by late gadolinium enhancement cardiac magnetic resonance and hepatitis C virus infection in thalassemia major patients. Journal of Cardiovascular Medicine, 2015, 16, 689.	0.6	23
54	Incidence of haemoglobinopathies in Sicily: the impact of screening and prenatal diagnosis. International Journal of Clinical Practice, 2015, 69, 1129-1138.	0.8	20

#	Article	IF	Citations
55	Non-Transfusion-Dependent Thalassemia: A Complex Mix of Genetic Entities Yet to Be Fully Discovered. BioMed Research International, 2015, 2015, 1-2.	0.9	2
56	2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood, 2015, 126, 89-93.	0.6	62
57	Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease andÎ²-Thalassemia Patients. Hemoglobin, 2015, 39, 225-229.	0.4	34
58	Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major. Circulation: Cardiovascular Imaging, 2015, 8, e003230.	1.3	62
59	Coâ€inheritance of the rare Î² hemoglobin variants Hb Yaounde, Hb GÃ¶rwihl and Hb City of Hope with other alterations in globin genes: impact in genetic counseling. European Journal of Haematology, 2015, 94, 322-329.	1.1	5
60	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	1.2	69
61	Role of iron metabolism genetic determinants in response to chelation therapy in a cohort of Î²-thalassemia and sickle cell syndromes Italian patients. Thalassemia Reports, 2014, 4, .	0.1	1
62	Development and recent progresses of gene therapy for Î²-thalassemia. Thalassemia Reports, 2014, 4, .	0.1	0
63	Safe mobilization of CD34+ cells in adults with Î²-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood, 2014, 123, 1483-1486.	0.6	62
64	Quantification of <scp>HBG</scp> m<scp>RNA</scp> in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and betaâ€thalassemia. European Journal of Haematology, 2014, 92, 66-72.	1.1	18
65	Identification of three new nucleotide substitutions in the Î²â€globin gene: laboratoristic approach and impact on genetic counselling for betaâ€thalassaemia. European Journal of Haematology, 2014, 92, 444-449.	1.1	7
66	Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells, Molecules, and Diseases, 2014, 53, 265-271.	0.6	17
67	Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. Blood Cells, Molecules, and Diseases, 2013, 51, 85-88.	0.6	19
68	Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death. Blood Cells, Molecules, and Diseases, 2013, 50, 241-246.	0.6	9
69	Iron load. Thalassemia Reports, 2013, 3, 5.	0.1	0
70	Cerebrovascular events in sickle cellâ€beta thalassemia treated with hydroxyurea: A single center prospective survey in adult Italians. American Journal of Hematology, 2013, 88, E261-4.	2.0	18
71	Mosaic segmental uniparental isodisomy and progressive clonal selection: a common mechanism of late onset Â-thalassemia major. Haematologica, 2013, 98, 691-695.	1.7	11
72	Iron deficiency does not compromise the diagnosis of high HbA2 Â thalassemia trait. Haematologica, 2012, 97, 472-473.	1.7	26

#	Article	IF	Citations
73	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica, 2012, 97, 679-686.	1.7	46
74	Longâ€term use of deferiprone significantly enhances leftâ€ventricular ejection function in thalassemia major patients. American Journal of Hematology, 2012, 87, 732-733.	2.0	30
75	The genetic heterogeneity of Î²-globin gene defects in Sicily reflects the historic population migrations of the island. Blood Cells, Molecules, and Diseases, 2011, 46, 282-287.	0.6	32
76	Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules, and Diseases, 2011, 47, 166-175.	0.6	50
77	Reliability of EMA Binding Test in the Diagnosis of Hereditary Spherocytosis in Italian Patients. Acta Haematologica, 2011, 125, 136-140.	0.7	13
78	Feasibility of DNA diagnosis of haemoglobinopathies on coelocentesis. British Journal of Haematology, 2011, 153, 268-272.	1.2	16
79	Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies. British Journal of Haematology, 2011, 154, 659-661.	1.2	7
80	Chelation treatment in sickleâ€cellâ€anaemia: much ado about nothing?. British Journal of Haematology, 2011, 154, 545-555.	1.2	29
81	Regional and global pancreatic T*₂ MRI for iron overload assessment in a large cohort of healthy subjects: Normal values and correlation with age and gender. Magnetic Resonance in Medicine, 2011, 65, 764-769.	1.9	38
82	Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica, 2011, 96, 41-47.	1.7	129
83	Sequential Alternating Deferiprone And Deferoxamine Treatment Compared To Deferiprone Monotherapy: Main Findings And Clinical Follow-Up Of A Large Multicenter Randomized Clinical Trial In -Thalassemia Major Patients. Hemoglobin, 2011, 35, 206-216.	0.4	21
84	Co-inheritance of Hb Hershey [Î²70(E14) Alaâ†'Gly] and Hb La Pommeraie [Î²133(H11)Valâ†'Met] in a Sicilian subject. European Journal of Haematology, 2010, 84, 453-457.	1.1	1
85	Embryoâ€fetal erythroid megaloblasts in the human coelomic cavity. Journal of Cellular Physiology, 2010, 225, 385-389.	2.0	9
86	Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patients. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	0
87	Glucose 6â€phosphate dehydrogenase Palermo R257M: a novel variant associated with chronic nonâ€spherocytic haemolytic anaemia. British Journal of Haematology, 2010, 149, 296-297.	1.2	4
88	Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. British Journal of Haematology, 2010, 150, 245-247.	1.2	44
89	Desensitization to hydroxycarbamide following longâ€term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. British Journal of Haematology, 2010, 151, 509-515.	1.2	41
90	Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in Î²â€thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 52-58.	1.8	29

#	Article	IF	Citations
91	Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells, Molecules, and Diseases, 2010, 45, 136-139.	0.6	45
92	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood, 2010, 116, 2875-2883.	0.6	79
93	Nucleated red blood cells and soluble transferrin receptor in thalassemia syndromes: relationship with global and ineffective erythropoiesis. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1539-42.	1.4	14
94	Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart, 2009, 95, 1688-1693.	1.2	73
95	The Sea Urchin sns5 Insulator Protects Retroviral Vectors From Chromosomal Position Effects by Maintaining Active Chromatin Structure. Molecular Therapy, 2009, 17, 1434-1441.	3.7	16
96	IL-23R determines susceptibility in CrohnÊ¼s disease in a mediterranean area. Inflammatory Bowel Diseases, 2009, 15, 317-318.	0.9	5
97	Influence of myocardial fibrosis and blood oxygenation on heart T2* values in thalassemia patients. Journal of Magnetic Resonance Imaging, 2009, 29, 832-837.	1.9	28
98	Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron. Journal of Magnetic Resonance Imaging, 2009, 30, 62-68.	1.9	115
99	Longâ€term sequential deferiproneâ€“deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. British Journal of Haematology, 2009, 145, 245-254.	1.2	68
100	The significance of the hemoglobin A2 value in screening for hemoglobinopathies. Clinical Biochemistry, 2009, 42, 1786-1796.	0.8	72
101	Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells, Molecules, and Diseases, 2009, 42, 247-251.	0.6	85
102	IN UTERO HAEMATOPOIETIC STEM CELL TRANSPLANTATION (IUHSCT). Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009031.	0.5	4
103	New analytical tools and epidemiological data for the identification of HbA2 borderline subjects in the screening for beta-thalassemia. Bioelectrochemistry, 2008, 73, 137-140.	2.4	33
104	Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients. British Journal of Haematology, 2008, 141, 720-727.	1.2	10
105	Hb Southern Italy: coexistence of two missence mutations (the Hb Sun Prairie Î±₂ 130 Ala â†') Tj ETQq1 1 0.784314 rgB Haematology, 2008, 143, 138-142.	1.2	4
106	Standardized T2* Map of a Normal Human Heart to Correct T2* Segmental Artefacts; Myocardial Iron Overload and Fibrosis in Thalassemia IntermediaVersusThalassemia Major Patients and Electrocardiogram Changes in Thalassemia Major Patients. Hemoglobin, 2008, 32, 97-107.	0.4	20
107	The Role of CARD15 Mutations and Smoking in the Course of Crohn's Disease in a Mediterranean Area. American Journal of Gastroenterology, 2008, 103, 649-655.	0.2	23
108	Significance of borderline hemoglobin A2 values in an Italian population with a high prevalence of Â-thalassemia. Haematologica, 2008, 93, 1380-1384.	1.7	66

#	Article	IF	Citations
109	Guideline recommendations for heart complications in thalassemia major. Journal of Cardiovascular Medicine, 2008, 9, 515-525.	0.6	84
110	Multislice Multiecho T2* Cardiovascular Magnetic Resonance Detects Heterogeneous Myocardial Iron Distribution in Thalassemia Patients. Blood, 2008, 112, 3877-3877.	0.6	0
111	Magnetic Resonance T2* Technique for Segmental and Global Quantification of Myocardial Iron : Multi-Centre Validation in the MIOT (Myocardial Iron Overload in Thalassemia) Network. Blood, 2008, 112, 5420-5420.	0.6	0
112	Therapeutic Options for Patients with Severe Î²-Thalassemia: The Need for Globin Gene Therapy. Human Gene Therapy, 2007, 18, 1-9.	1.4	48
113	External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems. Clinical Chemistry and Laboratory Medicine, 2007, 45, 88-92.	1.4	24
114	HCV Clearance Among Hemophiliacs and Beta-Thalassemics. Gastroenterology, 2007, 132, 1634.	0.6	5
115	StandardizedT2* map of normal human heartin vivo to correctT2* segmental artefacts. NMR in Biomedicine, 2007, 20, 578-590.	1.6	119
116	Light and shadows in the iron chelation treatment of haematological diseases. British Journal of Haematology, 2007, 138, 407-421.	1.2	73
117	Typing of the immunological system in human embryos by coelocentesis. European Journal of Haematology, 2007, 79, 435-438.	1.1	4
118	Incidence of Crohnâ€™s disease and CARD15 mutation in a small township in Sicily. European Journal of Epidemiology, 2007, 21, 887-892.	2.5	22
119	Deferiprone Versus Sequential Deferiprone-Deferoxamine Treatment in Thalassemia Major: A Five Years Multicenter Randomized Clinical Trial under the Auspices of the Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE).. Blood, 2007, 110, 575-575.	0.6	5
120	Hb Marineo [Î²70(E14)Alaâ†'Val]: A Silent Hemoglobin Variant with a Mutation Within the Heme Pocket. Hemoglobin, 2006, 30, 139-148.	0.4	11
121	A Prospective Study of Hepatocellular Carcinoma Incidence in Thalassemia. Hemoglobin, 2006, 30, 119-124.	0.4	66
122	Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. British Journal of Haematology, 2006, 133, 105-106.	1.2	27
123	A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nature Biotechnology, 2006, 24, 89-94.	9.4	114
124	Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. European Journal of Haematology, 2006, 76, 183-192.	1.1	115
125	Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. Journal of Magnetic Resonance Imaging, 2006, 23, 662-668.	1.9	173
126	Long-Term Outcome of Iron-Induced Cardiac Disease in Patients with Thalassemia Major Treated with Combined DFP/DFO or DFO Alone.. Blood, 2006, 108, 1764-1764.	0.6	1

#	Article	IF	Citations
127	Therapeutic Options for Patients with Severe?-Thalassemia: The Need for Globin Gene Therapy. Human Gene Therapy, 2006, .	1.4	0
128	Risk factors for death in patients with beta-thalassemia major: results of a case-control study. Haematologica, 2006, 91, 1420-1.	1.7	20
129	Analysis of delta-globin gene alleles in the Sicilian population: identification of five new mutations. Haematologica, 2006, 91, 1681-4.	1.7	32
130	Analytical evaluation of the Tosoh HLC-723 G7 automated HPLC analyzer for hemoglobin A2 and F determination. Clinical Biochemistry, 2005, 38, 159-165.	0.8	12
131	Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spectroscopy. British Journal of Haematology, 2005, 131, 135-140.	1.2	11
132	Allele-specific transcription of fetal genes in primary erythroid cell cultures from Lepore and Î²Â° thalassemia patients. Experimental Hematology, 2005, 33, 1363-1370.	0.2	7
133	Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies. European Journal of Haematology, 2005, 75, 267-269.	1.1	4
134	Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. American Journal of Hematology, 2005, 78, 158-159.	2.0	31
135	Intestinal Permeability and Genetic Determinants in Patients, First-Degree Relatives, and Controls in a High-Incidence Area of Crohn's Disease in Southern Italy. American Journal of Gastroenterology, 2005, 100, 2730-2736.	0.2	66
136	Functional characterization of the sea urchin sns chromatin insulator in erythroid cells. Blood Cells, Molecules, and Diseases, 2005, 35, 339-344.	0.6	7
137	Incidence of Pulmonary Hypertension in Haemoglobinopathic Patients without Left Ventricular Disfunction.. Blood, 2005, 106, 2691-2691.	0.6	3
138	Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 2004, 124, 114-117.	1.2	147
139	Independent clinical trials. Lancet, The, 2004, 363, 1080.	6.3	9
140	Rapid detection of six common Mediterranean and three non-Mediterranean ?-thalassemia point mutations by reverse dot blot analysis. American Journal of Hematology, 2003, 74, 191-195.	2.0	19
141	Cardiac complications in thalassemia: noninvasive detection methods and new directions in the clinical management. Expert Review of Cardiovascular Therapy, 2003, 1, 439-452.	0.6	8
142	Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone During a Randomized Multicenter Prospective Clinical Study. Hemoglobin, 2003, 27, 63-76.	0.4	31
143	Successful application of preimplantation genetic diagnosis for beta-thalassaemia and sickle cell anaemia in Italy. Human Reproduction, 2002, 17, 1158-1165.	0.4	22
144	Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial. Blood Cells, Molecules, and Diseases, 2002, 28, 196-208.	0.6	165

#	Article	IF	Citations
145	The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology, 2002, 118, 330-336.	1.2	192
146	A Region Upstream of the Human Î´-Globin Gene Shows a Stage-Specific Interaction with Globin Promoters in Erythroid Cell Lines. Blood Cells, Molecules, and Diseases, 2001, 27, 874-881.	0.6	5
147	Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in Î²-thalassemia intermedia patients. Free Radical Research, 2001, 34, 529-540.	1.5	77
148	CLINICAL AND HEMATOLOGICAL RESPONSES TO HYDROXYUREA IN SICILIAN PATIENTS WITH Hb S/Î²-THALASSEMIA. Hemoglobin, 2001, 25, 9-17.	0.4	22
149	Evidence of alloreactive T lymphocytes in fetal liver: implications for fetal hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2000, 25, 135-141.	1.3	33
150	In utero fetal liver hematopoietic stem cell transplantation: is there a role for alloreactive T lymphocytes?. Blood, 2000, 96, 1608-1609.	0.6	13
151	MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease.. American Journal of Roentgenology, 1999, 173, 1477-1480.	1.0	73
152	HEPATIC SICKLING. Transplantation, 1999, 67, 65-68.	0.5	21
153	Oxidation resistance of LDL is correlated with vitamin E status in Î²-thalassemia intermedia. Atherosclerosis, 1998, 137, 429-435.	0.4	37
154	Oxidative modification of low-density lipoprotein and atherogenetic risk in beta-thalassemia. Blood, 1998, 92, 3936-42.	0.6	15
155	Clinical and Hematological Response to Hydroxyurea in a Patient with Hb Leporbp-Thalassemia. Hemoglobin, 1997, 21, 219-226.	0.4	29
156	Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood, 1997, 90, 2207-12.	0.6	62
157	An element upstream from the human Î´-globin-encoding gene specifically enhances Î²-globin reporter gene expression in murine erythroleukemia cells. Gene, 1996, 168, 237-241.	1.0	3
158	LACK OF EVIDENCE OF PERMANENT ENGRAFTMENT AFTER IN UTERO FETAL STEM CELL TRANSPLANTATION IN CONGENITAL HEMOGLOBINOPATHIES1. Transplantation, 1996, 61, 1176-1179.	0.5	121
159	Evidence of induced non-tolerance in HLA-identical twins with hemoglobinopathy after in utero fetal transplantation. Bone Marrow Transplantation, 1996, 18, 637-9.	1.3	20
160	Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Human Genetics, 1995, 95, 526-530.	1.8	37
161	Evidence for a Globin Promoter-Specific Silencer Element Located Upstream of the Human Î´-Globin Gene. Biochemical and Biophysical Research Communications, 1994, 204, 413-418.	1.0	15
162	Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia.. Gut, 1993, 34, S142-S143.	6.1	16

#	Article	IF	Citations
163	Amplification of ETS2 oncogene in acute nonlymphoblastic leukemia with t(6;21;18). Cancer Genetics and Cytogenetics, 1992, 58, 71-75.	1.0	16
164	Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. Journal of Medical Virology, 1992, 38, 200-206.	2.5	38
165	alpha-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia. Haematologica, 1992, 77, 502-6.	1.7	11
166	The risks of early cordocentesis (12â€“21 weeks): Analysis of 500 procedures. Prenatal Diagnosis, 1990, 10, 425-428.	1.1	86
167	Sickle hemoglobinopathies in sicily. American Journal of Hematology, 1990, 33, 81-85.	2.0	41
168	The Regulation of ?-Globin Gene Expression. Annals of the New York Academy of Sciences, 1990, 612, 160-166.	1.8	2
169	The spectrum of Î²-thalassaemia mutations in Sicily. British Journal of Haematology, 1988, 69, 393-397.	1.2	44
170	Î²A and Î²thal DNA haplotypes in Sicily. Human Genetics, 1986, 72, 229-230.	1.8	23
171	Hemoglobin Phenotype and Mean Erythrocyte Volume in Sicilian People. Acta Haematologica, 1984, 71, 214-214.	0.7	8